Anti-inflammatory effects of kudingcha methanol extract (Ilex kudingcha C.J. Tseng) in dextran sulfate sodium-induced ulcerative colitis

Molecular Medicine Reports

Volumn 8, Issue 4, 2013, Pages 1256-1262

  Song, Jia Le ^a   Qian, Yu ^b   Li, Gui Jie ^b   Zhao, Xin ^b  

^a Pusan National University   (South Korea)

^b CHONGQING UNIVERSITY OF EDUCATION   (China)

Author keywords

Anti inflammation; Colitis; Dextran sulfate sodium; Ilex kudingcha C.J. Tseng

Indexed keywords

CYCLOOXYGENASE 2; CYTOKINE; DEXTRAN SULFATE; EOSIN; GLUTATHIONE; HEMATOXYLIN; ILEX KUDINGCHA PLANT EXTRACT; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MALONALDEHYDE; MESSENGER RNA; MYELOPEROXIDASE; PLANT EXTRACT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; HERBACEOUS AGENT; METHANOL; NOS2 PROTEIN, MOUSE; PTGS2 PROTEIN, MOUSE; SOLVENT;

ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY WEIGHT; COLON; CONTROLLED STUDY; DESCENDING COLON; DISEASE ACTIVITY; EDEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HISTOLOGY; ILEX; ILEX KUDINGCHA; LIPID PEROXIDATION; MALE; MOUSE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ULCERATIVE COLITIS; WEIGHT GAIN; WEIGHT REDUCTION; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; CHEMISTRY; COLITIS, ULCERATIVE; DRUG EFFECTS; DRUG SCREENING; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY;

ILEX; MUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; COLON; CYCLOOXYGENASE 2; CYTOKINES; DEXTRAN SULFATE; DRUG EVALUATION, PRECLINICAL; DRUGS, CHINESE HERBAL; GENE EXPRESSION; GLUTATHIONE; ILEX; MALE; MALONDIALDEHYDE; METHANOL; MICE; MICE, INBRED C57BL; NITRIC OXIDE SYNTHASE TYPE II; SOLVENTS;

EID: 84883377037     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1635     Document Type: Article

References (49)

1. Macdonald TT and Monteleone G: Immunity, inflammation, and allergy in the gut. Science 307: 1920-1925, 2005.
2. Bouma G and Strober W: The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 3: 521-533, 2003.
3. Ardizzone S and Bianchi Porro G: Biologic therapy for inflammatory bowel disease. Drugs 65: 2253-2286, 2005.
4. Hanauer SB: Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 12: S3-S9, 2006.
5. Podolsky DK: Inflammatory bowel disease. N Engl J Med 347: 417-429, 2002.
6. Rogler G and Andus T: Cytokines in inflammatory bowel disease. World J Surg 22: 382-389, 1998.
7. van Dieren JM, Kuipers EJ, Samsom JN, Nieuwenhuis EE and van der Woude CJ: Revisiting the immunomodulators tacrolimus, methotrexate, and mycophenolate mofetil: their mechanisms of action and role in the treatment of IBD. Inflamm Bowel Dis 12: 311-327, 2006.
8. Xu CT, Meng SY and Pan BR: Drug therapy for ulcerative colitis. World J Gastroenterol 10: 2311-2317, 2004.
9. Sun Y, Xu W, Zhang W, Hu Q and Zeng X: Optimizing the extraction of phenolic antioxidants from kudingcha made from Ilex kudingcha C.J. Tseng by using response surface methodology. Sep Sci Technol 78: 311-320, 2011.
10. Nishimura K, Fukuda T, Miyase T, Noguchi H and Chen XM: Activity-guided isolation of triterpenoid acyl CoA cholesteryl acyl transferase (ACAT) inhibitors from Ilex kudincha. J Nat Prod 62: 1061-1064, 1999.
11. Zhu F, Cai YZ, Sun M, Ke J, Lu D and Corke H: Comparison of major phenolic constituents and in vitro antioxidant activity of diverse kudingcha genotypes from Ilex kudingcha, Ilex cornuta, and Ligustrum robustum. J Agric Food Chem 57: 6082-6089, 2009.
12. Thuong PT, Su ND, Ngoc TM, Hung TM, Dang NH, Thuan ND, Bae K and Oh WK: Antioxidant activity and principles of Vietnam bitter tea Ilex kudingcha. Food Chem 113: 139-145, 2009.
13. Chen ZY, Wong IY, Leung MW, He ZD and Huang Y: Characterization of antioxidants present in bitter tea (Ligustrum pedunculare). J Agric Food Chem 50: 7530-7535, 2002.
14. Wong IY, He ZD, Huang Y and Chen ZY: Antioxidative activities of phenylethanoid glycosides from Ligustrum purpurascens. J Agric Food Chem 49: 3113-3119, 2001.
15. She GM, Wang D, Zeng SF, Yang CR and Zhang YJ: New phenylethanoid glycosides and sugar esters from ku-ding-cha, a herbal tea produced from Ligustrum purpurascens. J Food Sci 73: C476-C481, 2008.
16. Lau KM, He ZD, Dong H, Fung KP and But PP: Anti-oxidative, anti-inflammatory and hepato-protective effects of Ligustrum robustum. J Ethnopharmacol 83: 63-71, 2002.
17. Pu F, Mishima K, Irie K, Egashira N, Ishibashi D, Matsumoto Y, Ikeda T, Iwasaki K, Fujii H, Kosuna K and Fujiwara M: Differential effects of buckwheat and kudingcha extract on neuronal damage in cultured hippocampal neurons and spatial memory impairment induced by scopolamine in an eight-arm radial maze. J Health Sci 51: 636-644, 2005.
18. Kim JY, Jeong HY, Lee HK, Yoo JK, Bae K and Seong YH: Protective effect of Ilex latifolia, a major component of 'kudingcha', against transient focal ischemia-induced neuronal damage in rats. J Ethnopharmacol 133: 558-564, 2011.
19. Liu L, Sun Y, Laura T, Liang X, Ye H and Zeng X: Determination of polyphenolic content and antioxidant activity of Kudingcha made from Ilex kudingcha C.J. Tseng. Food Chem 112: 35-41, 2009.
20. Azuma YT, Nishiyama K, Matsuo Y, Kuwamura M, Morioka A, Nakajima H and Takeuchi T: PPAR contributes to colonic protection in mice with DSS-induced colitis. Int Immunopharmacol 10: 1261-1267, 2010.
21. Shin VY, Liu ES, Koo MW, Wang JY, Matsui H and Cho CH: Cigarette smoke extracts delay wound healing in the stomach: involvement of polyamine synthesis. Exp Biol Med (Maywood) 227: 114-124, 2002.
22. Gan XL, Hei ZQ, Huang HQ, Chen LX, Li SR and Cai J: Effect of Astragalus membranaceus injection on the activity of the intestinal mucosal mast cells after hemorrhagic shock-reperfusion in rats. Chin Med J (Engl) 119: 1892-1898, 2006.
23. Ellman GL: Tissue sulfhydryl groups. Arch Biochem Biophys 82: 70-77, 1959.
24. Strober W, Fuss IJ and Blumberg RS: The immunology of mucosal models of inflammation. Annu Rev Immunol 20: 495-549, 2002.
25. Hendrickson BA, Gokhale R and Cho JH: Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev 15: 79-94, 2002.
26. Yamamki K, Kim DH, Ryu N, Kim YP, Shin KH and Ohuchi K: Effects of naturally occurring isoflavones on prostaglandin E2 production. Planta Med 68: 97-100, 2002.
27. Cosnes J, Gower-Rousseau C, Seksik P and Cortot A: Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 140: 1785-1794, 2011.
28. Chung HL, Yue GG, To KF, Su YL, Huang Y and Ko WH: Effect of Scutellariae Radix extract on experimental dextran-sulfate sodium-induced colitis in rats. World J Gastroenterol 13: 5605-5611, 2007.
29. Langmead L, Dawson C, Hawkins C, Banna N, Loo S and Rampton DS: Antioxidant effects of herbal therapies used by patients with inflammatory bowel disease: an in vitro study. Aliment Pharmacol Ther 16: 197-205, 2002.
30. Malle E, Furtmüller P, Sattler W and Obinger C: Myeloperoxidase: a target for new drug development? Br J Pharmacol 152: 838-854, 2007.
31. Babbs CF: Oxygen radicals in ulcerative colitis. Free Radic Biol Med 13: 169-181, 1992.
32. Holma R, Salmenperä P, Riutta A, Virtanen I, Korpela R and Vapaatalo H: Acute effects of the cys-leukotriene-1 receptor antagonist, montelukast, on experimental colitis in rats. Eur J Pharmacol 429: 309-318, 2001.
33. Mustafa A, EI-Medany A, Hagar HH and EI-Medany G: Ginkgo biloba attenuates mucosal damage in a rat model of ulcerative colitis. Pharmacol Res 53: 324-330, 2006.
34. Osman N, Adawi D, Ahrné S, Jeppsson B and Molin G: Probiotics and blueberry attenuate the severity of dextran sulfate sodium (DSS)-induced colitis. Dig Dis Sci 53: 2464-2473, 2008.
35. Fiocchi C: Inflammatory bowel disease: new insights into mechanisms of inflammation and increasingly customized approaches to diagnosis and therapy. Curr Opin Gastroenterol 20: 309-310, 2004.
36. Dieleman LA, Palmen MJ, Akol H, Bloemena E, Peña AS, Meuwissen SG and Van Rees EP: Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 114: 385-391, 1998.
37. Bai A and Peng Z: Biological therapies of inflammatory bowel disease. Immunotherapy 2: 727-742, 2010.
38. Perrier C and Rutgeerts P: Cytokine blockade in inflammatory bowel diseases. Immunotherapy 3: 1341-1352, 2011.
39. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB and Lichtenstein GR, et al: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353: 2462-2476, 2005.
40. Duca I, Ramírez de la Piscina P, Estrada S, Calderón R, Spicakova K, Urtasun L, Marra-López C, Zabaleta S, Bengoa R, Marcaide MA and García-Campos F: Steroid-refractory ulcerative colitis and associated primary sclerosing cholangitis treated with infliximab. World J Gastroenterol 19: 590-593, 2013.
41. Siegmund B, Lehr HA, Fantuzzi G and Dinarello CA: IL-1 beta-converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci USA 98: 13249-13254, 2001.
42. Tountas NA, Casini-Raggi V, Yang H, Di Giovine FS, Vecchi M, Kam L, Melani L, Pizarro TT, Rotter JI and Cominelli F: Functional and ethnic association of allele 2 of the interleukin-1 receptor antagonist gene in ulcerative colitis. Gastroenterology 117: 806-813, 1999.
43. Dionne S, D'Agata ID, Hiscott J, Vanounou T and Seidman EG: Colonic explant production of IL-1 and its receptor antagonist is imbalanced in inflammatory bowel disease (IBD). Clin Exp Immunol 112: 435-442, 1998.
44. Kwon KH, Murakami A, Hayashi R and Ohigashi H: Interleukin-1beta targets interleukin-6 in progressing dextran sulfate sodium-induced experimental colitis. Biochem Biophys Res Commun 337: 647-654, 2005.
45. Papadakis KA and Targan SR: Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 51: 289-298, 2000.
46. Dudhgaonkar S, Tandan SK, Kumar D, Raviprakash V and Kataria M: Influence of simultaneous inhibition of cyclooxygenase-2 and inducible nitric oxide synthase in experimental colitis in rats. Inflammopharmacology 15: 188-195, 2007.
47. Cross RK and Wilson KT: Nitric oxide in inflammatory bowel disease. Inflamm Bowel Dis 9: 179-189, 2003.
48. Martín A, Villegas I and Alarcón de la Lastra C: The COX-2 inhibitor, rofecoxib, ameliorates dextran sulphate sodium induced colitis in mice. Inflamm Res 54: 145-151, 2005.
49. Tanaka K, Suemasu S, Ishihara T, Tasaka Y, Arai Y and Mizushima T: Inhibition of both COX-1 and COX-2 and resulting decrease in the level of prostaglandins E2 is responsible for non-steroidal anti-inflammatory drug (NSAID)-dependent exacerbation of colitis. Eur J Pharmacol 603: 120-132, 2009.